[go: up one dir, main page]

AR052997A1 - Complejos hechos utilizando drogas de baja solubilidad - Google Patents

Complejos hechos utilizando drogas de baja solubilidad

Info

Publication number
AR052997A1
AR052997A1 ARP050105379A ARP050105379A AR052997A1 AR 052997 A1 AR052997 A1 AR 052997A1 AR P050105379 A ARP050105379 A AR P050105379A AR P050105379 A ARP050105379 A AR P050105379A AR 052997 A1 AR052997 A1 AR 052997A1
Authority
AR
Argentina
Prior art keywords
low solubility
solubility drugs
complexes made
complexes
substances
Prior art date
Application number
ARP050105379A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR052997A1 publication Critical patent/AR052997A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sustancias que incluyen un complejo que incluye un resto de droga ionicamente unido a un contra-ion; en donde la solubilidad del complejo es mayor que la solubilidad del resto de droga. Composiciones y formas de dosificacion elaboradas a partir de dichas sustancias y complejos; métodos para elaborar composiciones, sustancias y complejos; método para administrarlos a los pacientes.
ARP050105379A 2004-12-21 2005-12-20 Complejos hechos utilizando drogas de baja solubilidad AR052997A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63827304P 2004-12-21 2004-12-21
US11/301,832 US20060134204A1 (en) 2004-12-21 2005-12-12 Complexes made using low solubility drugs

Publications (1)

Publication Number Publication Date
AR052997A1 true AR052997A1 (es) 2007-04-18

Family

ID=36596115

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105379A AR052997A1 (es) 2004-12-21 2005-12-20 Complejos hechos utilizando drogas de baja solubilidad

Country Status (5)

Country Link
US (1) US20060134204A1 (es)
AR (1) AR052997A1 (es)
TW (1) TW200633722A (es)
UY (1) UY29290A1 (es)
WO (1) WO2006069133A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
US20210186879A1 (en) * 2016-03-07 2021-06-24 Double Bond Pharmaceuticals Ab Targeted delivery of hydrophilic drugs to lung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
EP1225916A1 (en) * 1999-11-01 2002-07-31 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing

Also Published As

Publication number Publication date
WO2006069133A3 (en) 2008-03-27
WO2006069133A2 (en) 2006-06-29
UY29290A1 (es) 2006-03-31
TW200633722A (en) 2006-10-01
US20060134204A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AR054689A1 (es) Mecanismo de visualizacion de dosis para un dispositivo para la administracion de farmacos
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
ECSP077285A (es) Método de montaje de dispositivos para la administración de fármacos
EA200802204A1 (ru) Применение ингибиторов dpp iv
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
EA201590847A1 (ru) Новые ингибиторы rock
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
AR047928A1 (es) Derivados de tetrahidropiridoindol
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
MX387113B (es) Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EA201070625A1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
AR052997A1 (es) Complejos hechos utilizando drogas de baja solubilidad
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
HRP20080146T3 (en) Preoperative treatment of post operative pain
EA200701615A1 (ru) Новые лекарственные средства для лечения заболеваний дыхательных путей
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
GT200800208A (es) Composición farmacèutica que comprende la combinación de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal